Axona is a medical food designed to provide an alternative energy source for the brains of people with mild to moderate Alzheimer’s disease. It was classified by the FDA as a medical food in 2009, meaning it falls into a category between a conventional food and a prescription drug. Its active ingredient is caprylidene, a compound derived from medium-chain triglycerides that the body converts into ketone bodies, which brain cells can use for fuel.
How Axona Works in the Brain
One of the earliest changes in Alzheimer’s disease is that brain cells lose their ability to efficiently use glucose, their primary fuel. This energy shortage contributes to cognitive decline as neurons struggle to function. Axona is built around a simple idea: if the brain can’t use sugar well, give it a different fuel.
The active ingredient is caprylic triglyceride, an eight-carbon medium-chain triglyceride. When you consume it, your liver breaks it down into ketone bodies, the same molecules your body produces during fasting or on a very low-carb diet. These ketone bodies cross into the brain and provide energy to neurons through a pathway that doesn’t depend on glucose. In animal studies, caprylic triglyceride roughly doubled the concentration of circulating ketones in the blood compared to a control diet (0.54 vs. 0.22 mmol/L), confirming that oral intake meaningfully raises ketone levels available to the brain.
What the Clinical Evidence Shows
The primary clinical trial behind Axona is known as the AC-1202 study, a randomized, double-blind, placebo-controlled, multicenter trial in people with mild to moderate Alzheimer’s disease. The study found that AC-1202 (the research name for the same formulation) rapidly elevated ketone levels in participants and produced significant improvements on the ADAS-Cog, a standard test used to measure cognitive function in Alzheimer’s trials.
The improvements were not uniform across all participants. People who did not carry the APOE4 gene variant showed the most notable cognitive benefits when they were compliant with the dosing schedule. APOE4 is the strongest genetic risk factor for late-onset Alzheimer’s, carried by roughly 25% of the population. Why carriers responded less well isn’t fully understood, but it suggests that the way the brain processes ketones may differ depending on genetic makeup. This is an important detail: Axona appears to work better for some people than others based on a genetic factor that can be identified through testing.
Medical Food Classification
Axona is not a drug. The FDA classifies it as a medical food, a specific regulatory category for products that address a nutritional need in a disease or condition that cannot be met by simply changing what someone eats. Medical foods don’t go through the same approval process as pharmaceutical drugs, which means they face less rigorous testing requirements before reaching the market. They are, however, intended to be used under medical supervision.
This classification is important because it shapes what Axona’s manufacturer can and cannot claim. The product is marketed for the “clinical dietary management” of Alzheimer’s disease, not as a treatment or cure. Some clinicians and researchers have debated whether medium-chain triglycerides truly qualify as addressing a nutritional deficiency unique to Alzheimer’s patients, since ketone production is a normal metabolic process available to anyone. This debate hasn’t changed Axona’s legal status, but it’s worth understanding that the evidence base behind it is smaller than what would be required for an FDA-approved drug.
How It’s Taken
Axona comes as a powder that is mixed into a liquid, typically taken once daily. It contains a concentrated dose of caprylic triglyceride, which makes it calorie-dense. The powder is usually mixed into a soft food or beverage and consumed with a meal to reduce stomach upset. Some people start with a partial dose and gradually increase to the full amount over several days.
Side Effects
The most common side effects are gastrointestinal. In clinical trials, participants taking Axona experienced digestive issues more frequently than those on placebo. These effects were generally described as transient and mild to moderate, including symptoms like diarrhea, bloating, nausea, and stomach discomfort. Most people tolerate it better when they take it with food and ramp up the dose gradually rather than starting at full strength.
Because Axona increases ketone body production, people with conditions that affect how their body handles ketones need to be cautious. This includes individuals with poorly controlled diabetes, where excess ketone production could contribute to a dangerous state called ketoacidosis. People with known sensitivities to milk or palm kernel products (common sources of medium-chain triglycerides) should also be aware of potential reactions.
Practical Considerations
Axona is not covered by most insurance plans because of its medical food classification. Out-of-pocket costs can be significant over months of continuous use. It’s also not available over the counter in most pharmacies and typically needs to be ordered through a healthcare provider or specialty distributor.
Some people have explored using generic coconut oil or MCT oil supplements as a less expensive alternative, since these also contain medium-chain triglycerides that convert to ketone bodies. However, Axona delivers a standardized, concentrated dose of a specific triglyceride (caprylic acid, the C8 chain length), which is more efficiently converted to ketones than the mixed-chain fats found in coconut oil. Whether this difference translates to meaningfully better cognitive outcomes hasn’t been tested in a head-to-head trial, but the pharmacokinetics favor the purified form.
For families considering Axona, the genetic dimension is worth discussing with a physician. Because the clinical trial data showed the clearest benefit in people without the APOE4 gene variant, knowing a patient’s APOE status could help set realistic expectations about whether the product is likely to help.